0001640334-19-001161.txt : 20190617 0001640334-19-001161.hdr.sgml : 20190617 20190617171242 ACCESSION NUMBER: 0001640334-19-001161 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20190611 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20190617 DATE AS OF CHANGE: 20190617 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Inmune Bio, Inc. CENTRAL INDEX KEY: 0001711754 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 475205835 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38793 FILM NUMBER: 19902065 BUSINESS ADDRESS: STREET 1: 1224 PROSPECT STREET STREET 2: SUITE 150 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 8589643720 MAIL ADDRESS: STREET 1: 1224 PROSPECT STREET STREET 2: SUITE 150 CITY: LA JOLLA STATE: CA ZIP: 92037 8-K 1 inmb_8k.htm FORM 8-K inmb_8k.htm

 

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 11, 2019

 

INMUNE BIO INC.

(Exact name of registrant as specified in charter)

 

Nevada

 

001-38793

 

47-5205835

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of incorporation)

 

File Number)

 

Identification No.)

 

1224 Prospect Street, Suite 150, La Jolla, CA 92037

(Address of Principal Executive Offices) (Zip Code)

 

(858) 964 3720

(Registrant’s Telephone Number, Including Area Code)

 

Not Applicable

(Former Name or Former Address, If Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

 

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock

IMNB

NASDAQ

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 
 
 
 

Item 7.01 Regulation FD Disclosure

 

On June 11, 2019, INmune Bio, Inc. (the “Company”) issued a press release (the “Release”) through NetworkNewsAudio, announcing that its Chief Executive Officer Dr. Raymond Tesi, M.D. and Chief Financial Officer David Moss, were interviewed by Stuart Smith, host of NetworkNewsAudio, regarding the Company’s novel approach to treating unsolved problems in cancer therapy and neurogenerative diseases such as Alzheimer’s.

 

A copy of the Release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. Exhibits 99.1 shall not be deemed “filed” for purposed of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act.

 

Item 9.01 Financial statements and Exhibits

 

(d) Exhibits.

 

Exhibit Number

 

Description

99.1

 

INmune Bio Feature in NetworkNewsWire Broadcast June 11, 2019

 
 

2

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

INMUNE BIO INC.

 

Date: June 17, 2019

By:

/s/ David Moss

 

David Moss

 

Chief Financial Officer

 

 

3

 

EX-99.1 2 inmb_ex991.htm EX - 99.1 inmb_ex991.htm

EXHIBIT 99.1

 

INmune Bio Inc. Featured in Exclusive NetworkNewsWire Broadcast

 

NEW YORK, June 11, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces the broadcast of its exclusive audio interview with NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community.

 

The interview can be heard at http://nnw.fm/94zqW.

 

Two of the co-founders of INmune Bio – CEO Dr. RJ Tesi, M.D. and CFO David Moss – join NNW host Stuart Smith for a discussion on the company’s novel approach to treating unsolved problems in cancer therapy and neurogenerative diseases such as Alzheimer’s.

 

“INmune Bio is a clinical stage biotech company, what does that mean? It means we are developing drugs to treat diseases that don’t have very good treatments,” Tesi says, also noting the company’s unique stance approach.

 

“It’s very unusual for a company to be focused on both cancer and neurodegenerative diseases such as Alzheimer’s, but that’s because we view Alzheimer’s disease as an immunologic disease,” he explains. “At least a third, probably closer to 50% of patients with Alzheimer’s Disease and dementia have chronic inflammation as an underlying cause of their cognitive decline. You need to manipulate the immune system to solve that problem and as an immunology company, we do that.”

 

INmune Bio differentiates itself from other immunology companies by focusing on the innate immune system while the majority conduct research on the adaptive immune system or T cells. The company’s clinical research and drug candidate pipeline centers on three promising approaches to treating diseases related to the innate immune system.

 

“Humans have two immune systems, the adaptive and the innate immune system, and they work together in this very elegant system,” Tesi says. “We’ve got all these great therapies to treat the adaptive immune system, diseases that relate to T cells, but we don’t have much to treat those diseases related to the innate immune system.”

 

INmune Bio’s INKmune™ biologic delivery system works by priming natural killer (NK) cells to attack hidden, residual cancer cells. The company’s INB03 checkpoint inhibitor targets myeloid derived suppressor cells which prevent a patient’s own immune system from attacking cancer cells. Also in the company’s pipeline is XPro1595, which targets the microglial immune cells of the brain that are a cause of neuroinflammation which can kill nerve cells and promote synaptic dysfunction or dementia in Alzheimer’s disease patients. A $1 million “Part the Cloud” grant awarded by the Alzheimer’s Association helps fund INmune Bio’s XPro1595 research program.

 
 
 
 
 

 

From an operational standpoint, 2019 has been a year of “firsts” for INmune Bio as the company went public and commenced trading on the NASDAQ. Additionally, subsequent financings and the Alzheimer’s Association grant provided funding to pursue further research on the company’s three drug candidates with ongoing phase I clinical trials generating data and upcoming phase II clinical trials in the planning stages.

 

About INmune Bio Inc.  INmune Bio Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (NK) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.

 

About NetworkNewsAudio  NetworkNewsAudio (NNA) , a NetworkNewsWire (NNW) Solution, allows you to sit back and listen to market updates, CEO interviews and a Company AudioPressRelease (APR). These audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio (NNA) can assist your company by cutting through the overload of information in today's market, NNA brings its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire (NNW) is where news, content and information converge. NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of more than 5,000 key syndication outlets across the nation.

 

For more information, visit: www.NetworkNewsAudio.com.

 

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.

 
 
 
 
 

 

Forward-Looking Statements  This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

 

Corporate Communications:

NetworkWire (NW)

New York, New York

www.NetworkNewsWire.com

212.418.1217 Office 

Editor@NetworkWire.com

 

 
 
 
 

 

GRAPHIC 3 inmb_ex991img1.jpg begin 644 inmb_ex991img1.jpg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end